A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Trial Profile

A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; EMD 640744 (Primary) ; Epacadostat (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunovaccine; Incyte Corporation
  • Most Recent Events

    • 29 Mar 2017 Immunovaccine expects to complete enrollment and issue topline data by the end of 2017, according to a company media release.
    • 29 Mar 2017 First interim results published in an Immunovaccine media release.
    • 06 Feb 2017 According to an Immunovaccine media release, company expects to announce top-line interim results for this trial by the end of March 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top